AD 210
Alternative Names: AD-210Latest Information Update: 28 Jan 2024
At a glance
- Originator Addpharma
- Class Antihyperlipidaemics; Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Hyperlipidaemia; Hypertension
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Hyperlipidaemia in South Korea
- 28 Jan 2024 No recent reports of development identified for phase-I development in Hypertension in South Korea
- 15 Dec 2020 AD 210 is available for licensing as of 15 Dec 2020. http://www.addpharma.co.kr/